Table 4

Effect of TLR2 and TLR9 SNPs for α-FP level and UICC pathologic stage in patients with hepatocellular carcinoma

Gene

SNP

Genotype

Odds Ratio (95% CI) †

P Value

Odds Ratio (95% CI) ‡

P Value


TLR2

rs7696323

C/C

1

1

C/T

0.623 (0.339 - 1.142)

0.126

0.703 (0.393 - 1.257)

0.235

T/T

0.639 (0.241 - 1.693)

0.368

0.402 (0.156 - 1.038)

0.060

rs1898830

A/A

1

1

A/G

0.491 (0.771 - 2.885)

0.235

1.434 (0.740 - 2.635)

0.237

G/G

2.137 (0.994 - 4.597)

0.052

1.304 (0.624 - 2.726)

0.480

rs11938228

C/C

1

1

A/C

1.702 (0.894 - 3.239)

0.106

1.421 (0.771 - 2.616)

0.260

A/A

1.656 (0.764 - 3.587)

0.201

1.458 (0.693 - 3.479)

0.590

rs3804099

T/T

1

1

C/T

1.140 (0.623 - 2.083)

0.671

1.160 (0.644 - 2.088)

0.621

C/C

0.808 (0.287 - 2.276)

0.686

1.308 (0.492 - 3.479)

0.590

rs3804100

T/T

1

1

C/T

1.192 (0.651 - 2.183)

0.569

1.232 (0.681 - 2.230)

0.490

C/C

0.706 (0.210 - 2.377)

0.575

0.940 (0.312 - 2.832)

0.913

TLR9

rs352140

C/C

1

1

C/T

0.928 (0.511 - 1.685)

0.805

0.875 (0.487 - 1.573)

0.655

T/T

0.465 (0.137 - 1.076)

0.054

0.595 (0.260 - 1.360)

0.218

rs352139

G/G

1

1

G/A

1.106 (0.609 - 2.008)

0.741

1.051 (0.587 - 1.884)

0.866

A/A

0.470 (0.171 - 1.292)

0.143

0.691 (0.288 - 1.656)

0.407


† α-FP level: > 400 ng/ml or < = 400 ng/ml

‡ UICC classification: stage I, II or stage III, IV

Junjie et al. BMC Cancer 2012 12:57   doi:10.1186/1471-2407-12-57

Open Data